Clifford Chance
Clifford Chance advises GE on global antitrust and merger clearance for its $21.4 billion sale of its BioPharma business
March 24, 2020
- Sharis A. Pozen, Marc Besen, Anastasios Tomtsis, Yong Bai, Torsten Syrbe
- Washington D.C., Düsseldorf, Brussels, Beijing,
Clifford Chance advises GE on global antitrust and merger clearance for its $21.4 billion sale of its BioPharma business
Leading international law firm Clifford Chance advised GE in obtaining US and global merger clearance in connection with the US$21.4 billion sale of its BioPharma business to Danaher. The merging parties announced the sale on February 25, 2019.
The deal was reviewed by antitrust authorities from eight jurisdictions and was cleared by all: the European Commission, Brazil's CADE, China's SAMR, the Japan Fair Trade Commission, the Korean Fair Trade Commission, the Israeli Competition Authority, the Russian Federal Antimonopoly Service and the US Federal Trade Commission.
The 13-month global antitrust review resulted in clearance with remedies, coordinated globally among the European Commission, China's SAMR, the Korean Fair Trade Commission and the US Federal Trade Commission.
The Firm advised on antitrust issues for clearances across all relevant jurisdictions. The team included partners Sharis Pozen (Washington, DC), Marc Besen (Düsseldorf), Anastasios Tomtsis (Brussels), Bai Yong (Beijing) and Torsten Syrbe (Moscow).
In China, Clifford Chance acted as international counsel, working with the PRC local counsel.
